RECEIVED CENTRAL FAX CENTER

NO. 6949 P. 4

JAN 2 7 2009

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Dean L. Engelhardt et al.

Serial No.:

10/713,183

Filed:

November 19, 2003

11010111201 10, 2000

Hor:

IN VITRO PROCESS FOR PRODUCING
MULTIPLE COPIES OF PRIMER SEQUENCE

FREE SPECIFIC NUCLEIC ACID

Group Art Unit: 1634

Examiner: Katherine D. Salmon

527 Madison Avenue (9thFloor) New York, NY 10022-4304 January 27, 2009

<u>FILED BY FACSIMILE</u> TO: (571) 273-8300

Mail Stop – Non-Fee Amendment Director of Patents P.O. Box 1450 Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. §1.116 (IN REPLY TO THE AUGUST 21, 2008 OFFICE COMMUNICATION)

Dear Sirs:

This paper (Amendment Under 37 C.F.R. §1.115) is in reply to the Office Communication mailed on August 21, 2008 in connection with the above-identified application. A reply to the August 21, 2008 Office Communication was originally due by November 21, 2008. This paper (Amendment Under 37 C.F.R. §1.115) is accompanied by Applicants' Request For Extension Of Time Under 37 C.F.R. §1.136(a) (Three Months) and authorization for the fee therefor. Upon granting of Applicants' Request, the new deadline will be February 21, 2009. Accordingly, this paper (Amendment Under 37 C.F.R. §1.115) will be considered as having been timely filed.

Enz-52(C2)

Dean L. Engelhardt et al. Serial No.: 10/718,391 Filed: November 19, 2003

Page 2 [Amendment Under 37 C.F.R. §1.115 (In Reply To The August 21, 2008 Office Communication)] --- January 27, 2008]

CERTIFICATE OF TRANSMISSION

I hereby certify that this paper (Amendment Under 37 C.F.R. §1.115 (In Reply To The August 21, 2008 Office Communication) (along with any documents referred to as attached or enclosed) Is being facsimile transmitted to the United States Patent and Trademarks (Fax No. 571-273-8300) on January 27,

TAN 27 2009

Date

Ronald C. Fedus Reg. No. 32,567

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper. The claim listing below will replace all prior claim listings.

Remarks begin on page 7 of this paper.